Abstract
In order to evaluate the relationships between gonadal steroid hormones and central dopaminergic (DA) tone, we have administered a 'weak' dopamine agonist drug (piribedil) in 12 normal women, who were postmenopausal for at least 5 yrs, and we have studied the effects on anterior pituitary hormone release. We observed a decrease of plasma PRL levels and an increase of plasma GH values with all doses (40, 60, 100 mg p.o.) of the drug employed. No consistent changes in plasma FSH, LH, ACTH and TSH were observed and no side effects were reported. These results were greatly different from those previously described in premenopausal women in whom dose-related effects were observed and were similar to those observed in normal male subjects. The differences in the response to piribedil observed in women before and after the menopause could be due to a different sexual steroid environment.
| Original language | English |
|---|---|
| Pages (from-to) | 30-34 |
| Number of pages | 5 |
| Journal | Hormone and Metabolic Research |
| Volume | 23 |
| Issue number | 1 |
| Publication status | Published - 1991 |
Fingerprint
Keywords
- dopamine
- estrogens
- GH
- menopause
- piribedil
- PRL
ASJC Scopus subject areas
- Biochemistry
- Endocrinology
Cite this
Evaluation of dopaminergic tone in postmenopausal women : Effects of piribedil on anterior pituitary hormones. / De Marinis, L.; Mancini, A.; Calabro, F.; Sciuto, R.; Fiumara, C.; Zuppi, P.; Saporosi, A.; Barini, A.; Menini, E.
In: Hormone and Metabolic Research, Vol. 23, No. 1, 1991, p. 30-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of dopaminergic tone in postmenopausal women
T2 - Effects of piribedil on anterior pituitary hormones
AU - De Marinis, L.
AU - Mancini, A.
AU - Calabro, F.
AU - Sciuto, R.
AU - Fiumara, C.
AU - Zuppi, P.
AU - Saporosi, A.
AU - Barini, A.
AU - Menini, E.
PY - 1991
Y1 - 1991
N2 - In order to evaluate the relationships between gonadal steroid hormones and central dopaminergic (DA) tone, we have administered a 'weak' dopamine agonist drug (piribedil) in 12 normal women, who were postmenopausal for at least 5 yrs, and we have studied the effects on anterior pituitary hormone release. We observed a decrease of plasma PRL levels and an increase of plasma GH values with all doses (40, 60, 100 mg p.o.) of the drug employed. No consistent changes in plasma FSH, LH, ACTH and TSH were observed and no side effects were reported. These results were greatly different from those previously described in premenopausal women in whom dose-related effects were observed and were similar to those observed in normal male subjects. The differences in the response to piribedil observed in women before and after the menopause could be due to a different sexual steroid environment.
AB - In order to evaluate the relationships between gonadal steroid hormones and central dopaminergic (DA) tone, we have administered a 'weak' dopamine agonist drug (piribedil) in 12 normal women, who were postmenopausal for at least 5 yrs, and we have studied the effects on anterior pituitary hormone release. We observed a decrease of plasma PRL levels and an increase of plasma GH values with all doses (40, 60, 100 mg p.o.) of the drug employed. No consistent changes in plasma FSH, LH, ACTH and TSH were observed and no side effects were reported. These results were greatly different from those previously described in premenopausal women in whom dose-related effects were observed and were similar to those observed in normal male subjects. The differences in the response to piribedil observed in women before and after the menopause could be due to a different sexual steroid environment.
KW - dopamine
KW - estrogens
KW - GH
KW - menopause
KW - piribedil
KW - PRL
UR - http://www.scopus.com/inward/record.url?scp=0026020768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026020768&partnerID=8YFLogxK
M3 - Article
C2 - 1849868
AN - SCOPUS:0026020768
VL - 23
SP - 30
EP - 34
JO - Hormone and Metabolic Research
JF - Hormone and Metabolic Research
SN - 0018-5043
IS - 1
ER -